Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)

Summary

This is a phase 2, open-label, multicenter trial to evaluate the efficacy and safety of BN101 in subjects with Chronic Graft Versus Host Disease (cGVHD) after at least First Line of systemic therapy.

Timeline

Start

2021-04-27

Primary completion

2022-06-10

Completion

2022-12-10

Publications

• Wang Y, Wu D, Zhang X, Li Y, He Y, Liu Q, Xuan L, Li Z, Qi K, Sun Y, Wang S, Mo W, Gao L, Hua Y, Wang Y, Zhang Y. A phase II study of belumosudil for chronic graft-versus-host disease in patients who failed at least one line of systemic therapy in China. BMC Med. 2024 Mar 26;22(1):142. doi: 10.1186/s12916-024-03348-5.

Drugs

Indications